Abstract
This paper, Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force (1) is published within the context of the long-established heterogeneity of Alzheimer’s Disease (AD) pathology, as acknowledged by the authors. It is therefore inevitable that some form of combination therapy will be required to successfully modify disease pathology and provide an effective treatment. Gautier et al outline a number of scenarios for treatment, primarily focussing on either two independent therapies targeting different aspects of a pathway involving a single pathological substrate (for example, amyloid), or two therapies targeting different substrates (for example, amyloid and tau). The paper particularly considers the scenario of combined amyloid therapies and seeks to establish the most appropriate stage of disease for optimal application of this approach. Whilst the paper offers an extremely valuable insight into this specific aspect of combination therapy we would like to present a broader range of treatment scenarios where combination interventions may be of benefit.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
